Role of the p53/p21 system in the response of human colon carcinoma cells to doxorubicin

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Ravizza, Raffaella ^a   Gariboldi, Marzia B ^a   Passarelli, Laura ^a   Monti, Elena ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PROTEIN P21; PROTEIN P53; TEMPOL; AMINE OXIDE; ANTINEOPLASTIC ANTIBIOTIC; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN SYNTHESIS INHIBITOR; TUMOR PROTEIN;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; CALCULATION; CARCINOMA CELL; CLINICAL PROTOCOL; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SENSITIVITY; EPIGENETICS; GENETIC DISORDER; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; NEAR ISOGENIC LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; UPREGULATION; WESTERN BLOTTING; CELL PROLIFERATION; CELL STRAIN HT29; COLON TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; PHYSIOLOGY; SPIN LABELING; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIC N-OXIDES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HT29 CELLS; HUMANS; NEOPLASM PROTEINS; PROTEIN SYNTHESIS INHIBITORS; SPIN LABELS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13144288970     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-92     Document Type: Article

References (43)

1. Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Volume 5. IARC CancerBase Lyon, IARCPress; 2001.
2. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
3. Shah AM, Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001, 7:2168-2181.
4. Ferreira CG, Epping M, Kruyt FA, Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res 2002, 8: 024-2034.
5. Brown JM, Wilson G: Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther 2003, 2:477-490.
6. Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000, 102:1-4.
7. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108: 53-164.
8. Wang X: The expanding role of mitochondria in apoptosis. Genes Dev 2001, 15:2922-2933.
9. Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
10. Vousden K, Lu X: Live or let die: the cell's response to p53. Nature Rev Cancer 2002, 2:594-604.
11. Wallace-Brodeur RR, Lowe SW: Clinical implications of p53 mutations. Cell Mol Life Sci 1999, 55:64-75.
12. Herr I, Debatin MK: Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98:2603-2614.
13. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999, 104:263-269.
14. Liu X, Bishop WR, Liu M: Differential effects of cell cycle regulatory protein p21WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updates 2003, 6:183-195.
15. Gariboldi MB, Lucchi S, Caserini C, Supino R, Oliva C, Monti E: Antiproliferative effect of the piperidine nitroxide TEMPOL on neoplastic and nonneoplastic mammalian cell lines. Free Rad Biol Med 1998, 24:913-923.
16. Gariboldi MB, Rimoldi V, Supino R, Favini E, Monti E: The nitroxide TEMPOL induces oxidative stress, p21 WAF1/CIP1, and cell death in HL60 cells. Free Rad Biol Med 2000, 29:633-641.
17. Supino R: MTT assays. In In Methods in molecular biology: in vitro toxicity testing protocols Volume 43. Edited by: O'Hare SM, Atterwill CK. Totowa, NJ: Humana Press; 1998:137-149.
18. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
19. Yanez RJ, Porter AC: Influence of DNA delivery method on gene targeting frequencies in human cells. Somat Cell Mol Genet 1999, 25:27-31.
20. Kaeser MD, Pebernard S, Iggo RD: Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 2004, 279:7598-7605.
21. Kurz EU, Douglas P, Lees-Miller SP: Doxorubicin activates ATMdependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem in press. 2004, Oct 14
22. Take Y, Kumano M, Teraoka H, Nishimura S, Okuyama A: DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem Biophys Res Commun 1996, 221:207-212.
23. Gartel AL, Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999, 246:280-289.
24. Dotto GP: p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000, 1471:M43-M56.
25. Gartel AL, Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1: 39-649.
26. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ: p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997, 14:929-935.
27. Javelaud D, Besancon F: Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio. J Biol Chem 2002, 277: 7949-37954.
28. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas M, del C, Olive M, Hsieh JT, Logothetis CJ, Navone NM: p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002, 23:1289-1296.
29. Mahyar-Roemer M, Roemer K: p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001, 20:3387-3398.
30. Blagosklonny MV, Robey R, Bates S, Fojo T: Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000, 105:533-539.
31. Chopin V, Toillon RA, Jouy N, Le Bourhis X: p21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004, 23:21-29.
32. Agrawal S, Agarwal ML, Chatterjee-Kishore M, Stark GR, Chisolm GM: Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis. Mol Cell Biol 2002, 22:1981-1992.
33. Wu Q, Kirschmeier P, Hockenberry T, Yang TY, Brassard DL, Wang L, McClanahan T, Black S, Rizzi G, Musco ML, Mirza A, Liu S: Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem 2002, 277:36329-36337.
34. Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H: Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001, 7:1466-73.
35. Fulda S, Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004, 64: 37-346.
36. Satou M, Aizawa S, Hayakari M, Ookawa K, Tsuchida S: Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression. Cancer Sci 2003, 94: 86-291.
37. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nature Med 1997, 3:1233-1241.
38. Liu S, Bishop WR, Liu M: Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003, 6:183-195.
39. Roninson IB: Tumor cell senescence in cancer treatment. Cancer Res 2003, 63:2705-2715.
40. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP: DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002, 62:1876-1883.
41. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB: Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002, 99:389-394.
42. Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC, Roninson IB: p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene 2000, 19:2165-2170.
43. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J, Roninson IB: Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18:4808-4818.